Fig. 2: Establishment and validation of dCas9a-SAMKI/KI mice. | Nature Communications

Fig. 2: Establishment and validation of dCas9a-SAMKI/KI mice.

From: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance

Fig. 2

a Strategy for targeting of the dCas9a-SAM cassette into the mouse Rosa26 locus using CRISPR/Cas9 technology. Repair of the DNA cut by endogenous homology-directed repair (HDR) mechanism using homology sequences present in the pRosa26-dCas9a-SAM vector enables the insertion of the dCas9a-SAM cassette into the Rosa26 locus. b Long range PCR (LR–PCR) based validation of dCas9 expression in dCas9a-SAM transgenic mice. The expected product is 8609 bp. 2 independent experiments were performed showing similar results. c, d Representative flow cytometry data on eGFP expression or intracellular dCas9 staining in the indicated haematopoietic tissues derived from wildtype (WT, negative control) or dCas9a-SAMKI/KI mice. 3 WT mice and 4 dCas9a-SAMKI/KI mice were used for the analysis showing similar results. Source data are provided as a Source Data file.

Back to article page